1. FDA Approves Tecentriq Plus Avastin for Liver Cancer
The Food and Drug Administration has approved a regimen combining the immune checkpoint inhibitor Tecentriq (atezolizumab) and the targeted therapy Avastin (bevacizumab) for the treatment of people with inoperable or metastatic hepatocellular carcinoma, the most common type of liver cancer. more details...


2. FDA Approves Genentech’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic ® (cobimetinib) and Zelboraf ® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. more details...


3. FDA Grants Priority Review to Keytruda for Relapsed or Refractory Classical Hodgkin’s Lymphoma
he U.S. Food and Drug Administration (FDA) has accepted and given priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or refractory classical Hodgkin’s lymphoma (cHL). more details...


4. Lenvima to get benefit as 1st-line treatment of hepatocellular carcinoma
Lenvima (ingredient: lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to enjoy insurance benefit in the first-line treatment of hepatocellular carcinoma, the health authorities said. Eisai Korea released Lenvima in Korea about a year ago. more details...